KMTS
Kestra Medical Technologies, Ltd. Common Stock (KMTS) ESG Analysis Analysis (2026)
Environmental
R&D intensity of 20.5% of revenue suggests a comparatively innovation-oriented footprint, which can support product efficiency versus peers, though direct emissions data is unavailable.
Low debt-to-equity of 0.18 and net debt-to-EBITDA of 0.40 indicate limited balance-sheet pressure, which can reduce financing constraints on environmental investments versus leveraged peers.
The provided metrics do not disclose energy use, emissions, or waste performance, so environmental positioning cannot be confirmed as stronger than peers on core operational impacts.
Gross margin of 51.4% may indicate some ability to absorb compliance and transition costs, but it is not a direct environmental indicator and remains secondary to missing disclosure.
Social
Stock-based compensation at 24.5% of revenue suggests a heavy equity-based pay structure, which can align incentives but may also dilute employee value versus peers.
High R&D intensity can support workforce skill development and product quality, yet the absence of headcount, safety, and turnover data limits evidence of superior social performance.
No metrics are provided on labor relations, diversity, human capital retention, or customer responsibility, leaving social positioning broadly in line with disclosure-limited peers.
Moderate leverage supports operational continuity and can reduce stress on employees and suppliers, but this is an indirect social benefit rather than a core social strength.
Governance
Debt-to-equity of 0.18 and net debt-to-EBITDA of 0.40 indicate conservative leverage, which typically lowers creditor pressure and supports governance flexibility versus peers.
R&D intensity of 20.5% of revenue suggests disciplined capital allocation toward long-duration intangible assets, which can signal strategic oversight relative to peers.
Stock-based compensation at 24.5% of revenue is elevated, which can align management incentives but also raises dilution and compensation-governance scrutiny versus peers.
The absence of board composition, audit, ownership, and controversy data prevents a stronger governance assessment, so the score reflects only partial evidence.
Overall Score
KMTS appears moderately positioned versus peers, with conservative leverage and high R&D intensity offset by limited disclosure on core environmental, social, and governance indicators.
Score Driver: Conservative Leverage Combined With High R&D Intensity, Partially Offset By Incomplete ESG Disclosure.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kestra Medical Technologies, Ltd. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

